NDC 62484-0015-05 - XROMI
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 62484-0015
- Requested NDC
- 62484-0015-05
- Package NDCs from labels
- 62484-0015-4, 62484-0015-5, 62484-0015-05
- Manufacturer
- Nova Laboratories, Ltd. | Rare Disease Therapeutics, Inc. | Nova Laboratories, Ltd
- Effective date
- 2026-02-02
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| XROMI - Nova Laboratories, Ltd. | Rare Disease Therapeutics, Inc. | Nova Laboratories, Ltd | Nova Laboratories, Ltd. | Rare Disease Therapeutics, Inc. | Nova Laboratories, Ltd | 2026-02-02 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 62484-0015-4 | XROMI | 148 mL in 1 BOTTLE | SOLUTION | 148 | 10 | |
| 62484-0015-5 | XROMI | 1 in 1 CARTON | SOLUTION | 1 | 10 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 62484-0015 | XROMI (HYDROXYUREA) SOLUTION [NOVA LABORATORIES, LTD.] | 7 | Current NDC, 2 package rows | 20250105_4b37d336-86da-4363-aef1-34a7d3ba973b.zip |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 62484-0015-4 | ML - Milliliter | 62484-0015 | 111707d6-3307-4d5f-9438-5d129ab34881 | 1 | 2025-03-04 |
| 62484-0015-5 | ML - Milliliter | 62484-0015 | a1a06064-f010-4988-891b-23d18d367aac | 1 | 2025-03-04 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Hydroxyurea | HYDROXYUREA | Major Pharmaceuticals | e76fd60e-7644-48c5-9857-3608a045000b | 2026-05-27 | Warnings, Adverse reactions | X6Q56QN5QC |
| Hydroxyurea | HYDROXYUREA | Par Health USA, LLC | 9e1bdd4b-043a-4cf6-b1ff-8de49e02b7a6 | 2026-05-07 | Warnings, Adverse reactions | X6Q56QN5QC |
| Hydroxyurea | HYDROXYUREA | American Health Packaging | c84a2241-6c05-480f-8a5b-049e08c27d73 | 2026-03-02 | Warnings, Adverse reactions | X6Q56QN5QC |
| XROMI | HYDROXYUREA | Nova Laboratories, Ltd. | 4b37d336-86da-4363-aef1-34a7d3ba973b | 2026-02-02 | Boxed warning, Warnings, Adverse reactions | NDA216593 62484-0015-4 62484-0015-5 62484-0015 62484001505 2696079 2682741 6eb58656-a29b-4edb-966f-bc9a13a78775 4b37d336-86da-4363-aef1-34a7d3ba973b X6Q56QN5QC |
| HYDREA | HYDROXYUREA | H2-Pharma LLC | 6053c775-68de-45e4-9af9-33b18fd0e140 | 2026-01-26 | Warnings, Adverse reactions | X6Q56QN5QC |
| DROXIA | HYDROXYUREA | H2-Pharma LLC | a9494409-3571-4a81-9ad3-15ef7cb636a2 | 2026-01-26 | Boxed warning, Warnings, Adverse reactions | X6Q56QN5QC |
| Siklos | HYDROXYUREA | Medunik | 76957c0d-0f98-4376-bb06-eee651adc09d | 2026-01-07 | Boxed warning, Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Coupler LLC | 44fd5379-5fb0-ff62-e063-6294a90ac792 | 2025-12-02 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | AvKARE | 862583ff-6d5c-3f7d-e3bd-352fb0400928 | 2025-10-15 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDREA | HYDROXYUREA | Waylis Therapeutics LLC | 8d41152f-a98a-4abc-afdf-a909012434a0 | 2025-09-15 | Warnings, Adverse reactions | X6Q56QN5QC |
| DROXIA | HYDROXYUREA | Waylis Therapeutics LLC | 4ad13dc6-a2ab-4308-96b3-7c642c92cc23 | 2025-09-12 | Boxed warning, Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Golden State Medical Supply, Inc. | 1b42f2b4-3880-e7a9-e063-6294a90a5fd0 | 2024-11-25 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Leading Pharma, LLC | 4c4e1c2f-2143-44f3-8825-aeba42e755e4 | 2024-10-29 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Somerset Therapeutics, LLC | 9752a347-b42c-44d5-8fd1-c538f7f239dc | 2024-09-23 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Teva Pharmaceuticals USA, Inc. | b9514ae5-79ae-4cc2-9d7f-c8f7806d1694 | 2024-05-30 | Warnings, Adverse reactions | X6Q56QN5QC |
| HYDROXYUREA | HYDROXYUREA | Qilu Pharmaceutical Co., Ltd. | 4cd244d4-bd4a-41c8-b072-c2135787d412 | 2024-04-30 | Warnings, Adverse reactions | X6Q56QN5QC |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.